+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Anaplastic Astrocytoma Market: By Treatment By Molecule Development Phase & Geography - Forecast 2016-2021

  • ID: 3820955
  • Report
  • January 2016
  • Region: Global
  • 146 pages
  • IndustryARC
Anaplstic astrocytoma is a rare type of malignant brain tumor classified under WHO grade III in pathological classification system for tumors. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes which are present in human brain. Astrocytes along with other similar cells are involved in forming tissues that surrounds and protects other nerve cells found within the brain and spinal cord system which are collectively called glial cells and tissues formed by them is known as glial tissue. According to world health organization these astrocytoma tumors are classified into I to IV grades based on how fast the cells are reproducing and that likelihood that they will spread (infiltrate) nearby tissue. The signs and symptoms of these anaplastic astrocytoma vary depending upon the location and size of the tumor but most symptoms result from increased pressure within the brain. Other symptoms of these tumors include severe headache, focal neurological deficits, depression and sometimes seizures. Global increase in the reported instances of anaplastic astrocytoma is driving the demand and huge investment by major drug manufacturers in R&D activities to develop new molecules to cure this rare brain tumors.

This report identifies the global anaplastic astrocytoma market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global anaplastic astrocytoma market.

Globally North America contributed highest revenues in anaplastic astrocytoma market due to deep reach of the treatments to the large number of population followed by Europe and Asia-Pacific regions as the second and third largest markets for Anaplastic astrocytoma.

In these report global Anaplastic astrocytoma market is further segmented based on the basis of treatment, molecule development phase and geography type as follows:

Global Anaplastic Astrocytoma Market, By Treatment (2014-2021): Surgery, Radiation, and Chemotherapy
Global Anaplastic Astrocytoma Market, By Molecule Development Phase (2014-2021):Pre-Registration Phase, and Clinical Trail Phase (Phase I, Phase II, and Phase III)
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the global anaplastic astrocytoma market. Some of the major companies’ profiles in detail are as follows:

Isarna Therapeutics GmbH
Axelar AB
Amgen Inc.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
1. Anaplastic Astrocytoma – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Anaplastic Astrocytoma – Market Forces
4.1. Drivers
4.1.1. Globally increasing incidences of anaplastic astrocytoma
4.2. Restraints
4.2.1. Low awareness and R&D activities in developing countries
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Anaplastic Astrocytoma Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Global Anaplastic Astrocytoma Market, By Treatment (2014-2021)
6.1. Surgery
6.2. Radiation
6.3. Chemotherapy

7. Global Anaplastic Astrocytoma Market, By Molecule Development Phase (2014-2021)
7.1. Pre-Registration Phase
7.2. Clinical Trail Phase
7.2.1. Phase I
7.2.2. Phase II
7.2.3. Phase III

8. Global Anaplastic Astrocytoma Market, By Geography (2014-2021)
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Anaplastic Astrocytoma – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Top 10 Companies)
10.1. Genentech
10.1.1. Introduction
10.1.2. Financials
10.1.3. Key Insights
10.1.4. Key Strategy
10.1.5. Product Portfolio
10.1.6. SWOT Analysis
10.2. Isarna Therapeutics GmbH
10.2.1. Introduction
10.2.2. Financials
10.2.3. Key Insights
10.2.4. Key Strategy
10.2.5. Product Portfolio
10.2.6. SWOT Analysis
10.3. Axelar AB
10.3.1. Introduction
10.3.2. Financials
10.3.3. Key Insights
10.3.4. Key Strategy
10.3.5. Product Portfolio
10.3.6. SWOT Analysis
10.4. Pfizer
10.4.1. Introduction
10.4.2. Financials
10.4.3. Key Insights
10.4.4. Key Strategy
10.4.5. Product Portfolio
10.4.6. SWOT Analysis
10.5. Amgen Inc.
10.5.1. Introduction
10.5.2. Financials
10.5.3. Key Insights
10.5.4. Key Strategy
10.5.5. Product Portfolio
10.5.6. SWOT Analysis
10.6. Novartis
10.6.1. Introduction
10.6.2. Financials
10.6.3. Key Insights
10.6.4. Key Strategy
10.6.5. Product Portfolio
10.6.6. SWOT Analysis
10.7. Peregrine Pharmaceuticals, Inc.
10.7.1. Introduction
10.7.2. Financials
10.7.3. Key Insights
10.7.4. Key Strategy
10.7.5. Product Portfolio
10.7.6. SWOT Analysis
10.8. EirGen Pharma Ltd.
10.8.1. Introduction
10.8.2. Financials
10.8.3. Key Insights
10.8.4. Key Strategy
10.8.5. Product Portfolio
10.8.6. SWOT Analysis
10.9. Boehringer Ingelheim GmbH
10.9.1. Introduction
10.9.2. Financials
10.9.3. Key Insights
10.9.4. Key Strategy
10.9.5. Product Portfolio
10.9.6. SWOT Analysis
10.10. Celldex Therapeutics, Inc
10.10.1. Introduction
10.10.2. Financials
10.10.3. Key Insights
10.10.4. Key Strategy
10.10.5. Product Portfolio
10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Expert Insights
Note: Product cover images may vary from those shown